Drug that cuts risk of breast cancer returning is approved for use in England
Thousands of women with early breast cancer could be offered a drug to stop the cancer returning, after the medicines watchdog approved its use in England.
Up to 4,000 patients a year could be given ribociclib alongside hormone therapy, for hormone receptor-positive, HER2-negative early breast cancer, which despite initial treatment has a higher risk of returning.
Globally, one in 20 women will develop breast cancer in their lifetime, with cases up 38% and deaths up 68% over the next 25 years, according to latest analysis by the International Agency for Research on Cancer (IARC).
In the UK, breast cancer rates are expected to rise a fifth to 71,006 cases a year in 2050. The most common type of breast cancer – accounting for around 70% of cases – are hormone receptor-positive, HER2-negative tumours.
The National Institute for Health and Care Excellence (Nice) said the drug, known under the brand name Kisqali, will be available to patients with cancer that has spread to the lymph nodes and meets at least one of these criteria:
Cancer present in at least four lymph nodes, or
Cancer present in one to three lymph nodes that is either grade 3 (more advanced); or has a primary tumour at least 5cm in size.
Ribociclib targets and blocks proteins called CDK 4 and CDK 6, which play a role in cancer cell growth and division, helping to slow or stop tumour growth. It is taken as a pill twice a day, alongside an aromatase inhibitor, a hormone therapy that reduces oestrogen levels in the body.
Clinical trials show that combining ribociclib with an aromatase inhibitor may extend the time before cancer returns by up to 29%, compared with using an aromatase inhibitor alone.
The decision follows Nice approval earlier in April for capivasertib to treat advanced hormone receptor (HR)-positive HER2-negative breast cancer that has spread, which could benefit as many as 3,000 women a year.
But cancer charities said they were disappointed Nice did not approve ribociclib's use for those with other forms of early breast cancer at high risk of recurrence.
Claire Rowney, the chief executive of Breast Cancer Now, said: 'We're deeply concerned that thousands of people with early breast cancer could miss out on access to a vital type of treatment due to uncertainties around cost-effectiveness.
'Despite the promising potential for adjuvant ribociclib to cut the risk of cancer coming back by almost a third (28.5%), today's decision means only certain people with high-risk node positive disease, and none with high-risk node negative disease, would receive it.
'While drug approvals are always welcome, it's disappointing that so many people could be denied access to this vital treatment and the chance to alleviate some anxiety about their cancer returning.
'Nice and Novartis must urgently work together to resolve the uncertainties around cost-effectiveness, to ensure a swift change to guidance so that everyone who could benefit can receive adjuvant ribociclib.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
7 hours ago
- The Sun
Major boost to NHS as robotic surgery will slash stubbornly high waiting lists – but it'll take a decade
ROBOTIC surgery will slash waiting lists in a decade, the head of the NHS will say today. NHS England estimates robotic systems will be used in half a million operations a year by 2035, compared with 70,000 last year. That will include nine out of ten keyhole ops in the gut and pelvis, and increasing numbers of emergency surgeries. Health service boss Sir Jim Mackey will say at an NHS conference today: 'We have pledged to return to shorter elective waiting times by 2029 and we are using every tool at our disposal. 'Robotic surgery will play a huge part in this. 'Not only does it speed up the number of procedures the NHS can do, but it also means better outcomes, faster recoveries and shorter hospital stays.' Waiting lists in England are stubbornly high at 7.4million. The total increased in March as demand soared at a time of staff and cash shortages. Robot-assisted surgery uses super-precise mechanical arms that are electronically controlled by a surgeon and do internal operating work through tiny incisions on the body. They can be used for many common operations including hernia repairs, organ removals, hip and knee replacements and cancer treatment. Patients often have less blood loss, less scarring and need less anaesthetic, helping them recover faster. More than 140 robots are already in use across the UK. The NHS spending watchdog Nice recently approved 11 machines for use in England in the hope it will end a postcode lottery in their use.
The Independent
18 hours ago
- The Independent
Thousands could be saved by making this small change to heart failure treatment
New guidelines for treating heart failure could save 3,000 lives and prevent 5,500 hospital admissions every year, according to the National Institute for Health and Care Excellence (Nice). The draft guidelines recommend that medicines be administered up to a year earlier for a specific type of heart failure known as heart failure with reduced ejection fraction (HFrEF). This condition occurs when the left side of the heart struggles to pump blood effectively throughout the body. HFrEF affects approximately 387,000 of the 614,000 adults in England who suffer from heart failure. The new Nice guidelines aim to improve outcomes for these patients by ensuring timely and effective treatment. Nice said medics are already changing practice to ensure that the four pillars of treatment – angiotensin-converting enzyme inhibitor (ACEI), a beta-blocker (BB), a mineralocorticoid receptor antagonist (MRA) and a sodium-glucose cotransporter-2 (SGLT2) inhibitor – can be used earlier without the need to optimise the dose of any one medicine before introducing another. Nice is recommending widespread earlier use of the SGLT2 inhibitors empagliflozin and dapagliflozin – giving them at the start of treatment rather than waiting up to a year for dosage of other drugs to be optimised. Generally, Nice said the drugs can also be started by GPs with advice from a heart failure specialist, rather than having to refer people to hospitals. Eric Power, deputy director in Nice's centre for guidelines, said: 'Heart failure is common, with currently around 614,000 adults in England living with a diagnosis. 'Although there's no cure, it is treatable, and the growing number of people living with heart failure is testament to the improvements in care introduced over recent years. 'For this update we've been able to review the emerging evidence quickly to keep pace with changes in the treatment landscape and make recommendations that will widen access to effective treatments. 'This should have a big impact on the lives of people living with heart failure as well as freeing up space in hospitals by reducing their risk of having to go to hospital for unplanned emergency treatment.'
South Wales Argus
20 hours ago
- South Wales Argus
Around 3,000 lives could be saved ‘by changes to heart failure treatment'
New draft guidelines from the National Institute for Health and Care Excellence (Nice) recommend medicines are given up to a year earlier. It has looked specifically at a type of heart failure called heart failure with a reduced ejection fraction (HFrEF), which happens when the left side of the heart fails to pump blood out to the body properly. The condition affects around 387,000 of the 614,000 adults in England with heart failure. Nice said medics are already changing practice to ensure that the four pillars of treatment – angiotensin-converting enzyme inhibitor (ACEI), a beta-blocker (BB), a mineralocorticoid receptor antagonist (MRA) and a sodium-glucose cotransporter-2 (SGLT2) inhibitor – can be used earlier without the need to optimise the dose of any one medicine before introducing another. Nice is recommending widespread earlier use of the SGLT2 inhibitors empagliflozin and dapagliflozin – giving them at the start of treatment rather than waiting up to a year for dosage of other drugs to be optimised. Generally, Nice said the drugs can also be started by GPs with advice from a heart failure specialist, rather than having to refer people to hospitals. Eric Power, deputy director in Nice's centre for guidelines, said: 'Heart failure is common, with currently around 614,000 adults in England living with a diagnosis. 'Although there's no cure, it is treatable, and the growing number of people living with heart failure is testament to the improvements in care introduced over recent years. 'For this update we've been able to review the emerging evidence quickly to keep pace with changes in the treatment landscape and make recommendations that will widen access to effective treatments. 'This should have a big impact on the lives of people living with heart failure as well as freeing up space in hospitals by reducing their risk of having to go to hospital for unplanned emergency treatment.'
